PL417159A1 - Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera - Google Patents

Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera

Info

Publication number
PL417159A1
PL417159A1 PL417159A PL41715916A PL417159A1 PL 417159 A1 PL417159 A1 PL 417159A1 PL 417159 A PL417159 A PL 417159A PL 41715916 A PL41715916 A PL 41715916A PL 417159 A1 PL417159 A1 PL 417159A1
Authority
PL
Poland
Prior art keywords
seq
treatment
dendrimers
conjugates
application
Prior art date
Application number
PL417159A
Other languages
English (en)
Inventor
Krzysztof Nieznański
Hanna Nieznańska
Witold Surewicz
Krystyna Surewicz
Magdalena Bandyszewska
Original Assignee
Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego filed Critical Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego
Priority to PL417159A priority Critical patent/PL417159A1/pl
Priority to ES17728263T priority patent/ES2901053T3/es
Priority to PCT/IB2017/052733 priority patent/WO2017195131A1/en
Priority to PL17728263T priority patent/PL3468577T3/pl
Priority to US16/300,214 priority patent/US10815292B2/en
Priority to EP17728263.9A priority patent/EP3468577B1/en
Publication of PL417159A1 publication Critical patent/PL417159A1/pl
Priority to IL262902A priority patent/IL262902B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Niniejsze zgłoszenie dotyczy: pochodzących z PrP fragmentów peptydowych o SEQ ID NO: 1 lub SEQ ID NO: 2 lub SEQ ID NO: 3 lub SEQ ID NO: 4 do zastosowania jako lek w leczeniu patologii związanych z amyloidogenezą Aß i/lub związanej z Aß toksyczności, w szczególności choroby Alzheimera (AD); koniugatu obejmującego pochodzące z PrP fragmenty peptydowe o SEQ ID NO: 1 lub SEQ ID NO: 3 i/lub SEQ ID NO: 2 lub SEQ ID NO: 4 oraz cząsteczkę nośnika, przy czym cząsteczką nośnika jest cząsteczka farmakologicznie dopuszczalna, korzystnie dendrymer niskiej generacji, taki jak dendrymer PAMAM oraz sposobu wytwarzania powyższego koniugatu.
PL417159A 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera PL417159A1 (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
ES17728263T ES2901053T3 (es) 2016-05-11 2017-05-10 Conjugados proteína priónica-dendrímero para uso en el tratamiento de la enfermedad de Alzheimer
PCT/IB2017/052733 WO2017195131A1 (en) 2016-05-11 2017-05-10 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
PL17728263T PL3468577T3 (pl) 2016-05-11 2017-05-10 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera
US16/300,214 US10815292B2 (en) 2016-05-11 2017-05-10 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
EP17728263.9A EP3468577B1 (en) 2016-05-11 2017-05-10 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease
IL262902A IL262902B2 (en) 2016-05-11 2018-11-08 Prion protein-dendrimer conjugates for use in treatment of alzheimer disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera

Publications (1)

Publication Number Publication Date
PL417159A1 true PL417159A1 (pl) 2017-11-20

Family

ID=59014670

Family Applications (2)

Application Number Title Priority Date Filing Date
PL417159A PL417159A1 (pl) 2016-05-11 2016-05-11 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
PL17728263T PL3468577T3 (pl) 2016-05-11 2017-05-10 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17728263T PL3468577T3 (pl) 2016-05-11 2017-05-10 Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby alzheimera

Country Status (6)

Country Link
US (1) US10815292B2 (pl)
EP (1) EP3468577B1 (pl)
ES (1) ES2901053T3 (pl)
IL (1) IL262902B2 (pl)
PL (2) PL417159A1 (pl)
WO (1) WO2017195131A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112439074B (zh) * 2020-12-03 2022-09-13 浙江大学 可快速提高功能多肽亲和力的偶联物及其制备方法和应用
CN115737787B (zh) * 2022-12-15 2024-04-19 四川大学 乳铁蛋白联合胆碱在制备预防和/或治疗阿尔兹海默症的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128774A (en) 1994-03-07 2001-05-20 Dow Chemical Co Composition comprising a dendritic poymer in complex with at least one unit of biological response modifier and a process for the preparation thereof
KR19990029749A (ko) 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
PT1346041E (pt) * 2000-11-27 2007-06-05 Praecis Pharm Inc Agentes terapêuticos e métodos para a sua utilização no tratamento de uma doença amiloidogénica.
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
WO2005095633A1 (en) * 2004-04-02 2005-10-13 Queen's University At Kingston A cell culture system for modelling serum amyloid a amyloidogenesis and identifying amyloid modulating compounds
RU2408605C2 (ru) 2005-02-18 2011-01-10 Анджиокем Инк. Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
US9217036B2 (en) * 2007-04-26 2015-12-22 Yale University Prion protein as a receptor for amyloid-β oligomers
WO2009041902A1 (en) 2007-09-25 2009-04-02 Loefgren Kajsa Prion protein derived cell penetrating peptides and their uses
EP2885318A4 (en) * 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE DENDRIMER CONJUGATES AND ITS USES

Also Published As

Publication number Publication date
EP3468577A1 (en) 2019-04-17
IL262902B2 (en) 2023-02-01
IL262902A (en) 2019-03-31
WO2017195131A1 (en) 2017-11-16
US20190092837A1 (en) 2019-03-28
US10815292B2 (en) 2020-10-27
IL262902B (en) 2022-10-01
PL3468577T3 (pl) 2022-02-14
EP3468577B1 (en) 2021-09-15
ES2901053T3 (es) 2022-03-21

Similar Documents

Publication Publication Date Title
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
MX2012001194A (es) Peptidos tau antigenicos y usos de los mismos.
CY1119376T1 (el) Αντισωματα ειδικα για τη μορφη πρωτοϊνιδιου της βητα-αμυλοειδους πρωτεϊνης
CY1119197T1 (el) Μεθοδος παροχης νοσο-ειδικων μοριων και στοχων δeσμευσης
MX384227B (es) Anticuerpos y fragmentos de unión a antígenos para usarse en el tratamiento y la profilaxis de amiloidosis.
CR20130234A (es) Métodos de tratamiento de trastornos asociados con el fgf21
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
AR066987A1 (es) Anticuerpo monoclonal contra proteina beta-amiloide
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
CL2008001960A1 (es) Compuestos derivados de tetrahidropiranocromano, procedimiento de preparacion, composicion farmaceutica, util para inhibir gamma-secretasa, destinados al tratamiento de enfermedades neurodegenetarivas, enfermedad de alzheimer e inhibir el deposito de proteina amiloide.
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
PE20142115A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
ECSP13012609A (es) Composición farmacéutica
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
MX2011012677A (es) Conjugados de albumina-peptido amiloide y usos de los mismos.
EA202091482A1 (ru) Антитела
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
BR112013000603A2 (pt) anticorpos conjugados com lipídios
EA202091478A1 (ru) Антитела
MX2020001855A (es) Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides.
MX2024006771A (es) Forma cristalina de n-(2-cloro-3-((5-cloro-3-metil-4-oxo-3,4-dihid roquinazolin-6-il)amino)-4-fluorofenil)-3-fluoroazetidina-1-sulfo namida.